News Releases

News Releases

Webinar Presentation: A Closer Look at Working with Caregivers in Clinical Trials, Especially in Cases of Rare Diseases

RESEARCH TRIANGLE PARK, NC– April 18, 2019Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, will hold a Webinar about the role caregivers play in clinical trials, especially in trials that are focused on rare or neurological conditions. The Webinar will be presented free to attendees Monday, April 29, 2019 from 11 am – 12:15 pm Eastern Time.

The Webinar will address questions related to caregiver support of patients and alerts drug developers to the comprehensive end-to-end solutions that a clinical research organization can provide for the lifecycle of the trial, to help gain the information needed for its success. Lisa Dilworth, Synteract’s VP, Rare and Orphan Diseases, will address issues that drug developers and investigators need to take into consideration.

“Executing clinical trials successfully and obtaining quality, reliable data necessitates the engagement of not just the patient but the patient’s entire ecosystem, especially in rare or neurological illnesses where caregivers play indispensable roles in daily support of patients before, during, and after clinical trial involvement,” says Dilworth. “Subtle changes in a patient’s mood, behavior and even physicality may be picked up by a caregiver, even though the patient may not identify, recall or be able to articulate the same, due to their disease state. We want to teach drug development and investigative teams how to work with caregivers to gain reliable and valid information that can be used in trials.”   

To register for the Webinar, click here: https://xtalks.com/webinars/the-role-of-caregivers-in-clinical-trials-a-focus-on-rare-neurological-conditions/ 

About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. With 800 employees across 21 countries, Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

# # #
CONTACT:
Beth Walsh
beth@clearpointagency.com
760-230-2424

x

Submit RFI / RFP

..
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required